International journal of radiation oncology, biology, physics · 2026
Tumor Loss of the Y Chromosome Defines a Biological Phenotype Associated With Resistance to Radiation Therapy Across Cancer Types.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bourbonne Vincent, Hanna Gerard G, Park Henry S, Walsh Cathal, Slotman Ben J, Gately Kathy, Marignol Laure
Аннотация
PURPOSE: Sex-linked determinants of radiation therapy response remain poorly understood. We investigated whether tumor loss of the Y chromosome (LOY) is associated with biological and clinical features of radiation therapy resistance across cancer types.
METHODS AND MATERIALS: We integrated publicly available cancer cell-line experimental data sets and clinical data to evaluate the impact of LOY on radiation therapy response. The radiosensitivity of 125 cancer cell lines, stratified by Y chromosome status, was analyzed. Gene expression analyses were performed to identify biological pathways associated with LOY. Clinical associations were examined in 537 male patients treated with radiation therapy across multiple tumor types in The Cancer Genome Atlas.
RESULTS: LOY was associated with increased post-radiation therapy survival in cancer cell lines (P < .001). Transcriptomic analyses demonstrated LOY-associated alterations in DNA damage response, senescence, longevity, and proliferation pathways. In TCGA tumors, LOY was associated with remodeling of the tumor microenvironment, including altered immune and stromal signatures. Clinically, LOY was associated with inferior survival in common-support overlap-weighted analyses adjusted for age, tumor stage, and TCGA-defined tumor type.
CONCLUSIONS: These findings suggest that tumor LOY is associated with a distinct biological profile characterized by features of radioresistance and adverse clinical outcomes following radiation therapy. Further studies are warranted to determine whether LOY represents a clinically relevant sex-linked determinant of radiation therapy response.
METHODS AND MATERIALS: We integrated publicly available cancer cell-line experimental data sets and clinical data to evaluate the impact of LOY on radiation therapy response. The radiosensitivity of 125 cancer cell lines, stratified by Y chromosome status, was analyzed. Gene expression analyses were performed to identify biological pathways associated with LOY. Clinical associations were examined in 537 male patients treated with radiation therapy across multiple tumor types in The Cancer Genome Atlas.
RESULTS: LOY was associated with increased post-radiation therapy survival in cancer cell lines (P < .001). Transcriptomic analyses demonstrated LOY-associated alterations in DNA damage response, senescence, longevity, and proliferation pathways. In TCGA tumors, LOY was associated with remodeling of the tumor microenvironment, including altered immune and stromal signatures. Clinically, LOY was associated with inferior survival in common-support overlap-weighted analyses adjusted for age, tumor stage, and TCGA-defined tumor type.
CONCLUSIONS: These findings suggest that tumor LOY is associated with a distinct biological profile characterized by features of radioresistance and adverse clinical outcomes following radiation therapy. Further studies are warranted to determine whether LOY represents a clinically relevant sex-linked determinant of radiation therapy response.